PANDHA-25-P-0000_003354 DNA Aptamer-based Therapeutic Development
Closed Pre-Solicitation Posted
Not the latest version. See the latest special notice from .
- Solicitation number
- PANDHA-25-P-0000_003354
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Bangkok Krung Thep Maha Nakhon Thailand
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency is seeking a two-year research contract for developing DNA aptamer-based antimicrobial therapeutics targeting bacterial wound infections, specifically focused on Pseudomonas aeruginosa. The primary objectives include producing DNA aptamers that can bind to the bacterial pathogen, conjugating these aptamers with recombinant C1q protein and IgG Fc domain protein, and validating their binding capabilities. Interested contractors must submit a 3-page capabilities statement electronically by 10:00 AM ET on April 1, 2025, to Linda Hinson via email. The contract opportunity falls under the NAICS category 541714 for Research and Development in Biotechnology and PSC category B537 for Special Studies/Analysis in Medical/Health fields. Potential contractors should carefully review the Request for Information (RFI) and prepare their responses following the specified formatting guidelines, understanding that this is an information-gathering exercise and not a formal solicitation.
The pre-solicitation notice indicates no specific set-aside designations for this contract opportunity. The proposed work will involve delivering the developed C1q- and Fc-conjugated DNA aptamers to WRAIR, AFRIMS for testing in Bangkok, Thailand. While no specific award value or budget range is explicitly stated in the documents, the contract is structured as a two-year study requiring advanced biotechnological research capabilities. The research aims to create a biologic therapeutic with immunomodulatory antimicrobial activity, suggesting a complex and specialized project requiring significant scientific expertise. Respondents will need to demonstrate substantial technical competence in biotechnology research, particularly in DNA aptamer development and protein conjugation techniques.
Notice text
The objective of this contract is to conduct a two-year study on conjugated aptamers as antimicrobial agents to produce DNA aptamers conjugated with C1q- and Fc-domain proteins to create a biologic therapeutic with immunomodulatory antimicrobial activity against bacterial pathogens for wound infection. This shall include producing DNA aptamers that bind to the bacterial pathogen Pseudomonas aeruginosa; conjugating DNA aptamers to recombinant C1q protein and to recombinant IgG Fc domain protein to produce C1q- and Fc-conjugated DNA aptamers; validating that C1q- and Fc-conjugated DNA aptamers bind to Pseudomonas aeruginosa; and delivering C1q- and Fc-conjugated DNA aptamers to WRAIR, AFRIMS for testing, located in Bangkok, Thailand.
Files
| File | Type | Posted |
|---|---|---|
| A01-Request for Information PANDHA-25-P-0000 003354.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| PANDHA-25-P-0000_003354 DNA Aptamer-based Therapeutic Development | Special Notice | |
| This notice | Pre-Solicitation |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity